These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 32980406)
21. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Yuen CK; Lam JY; Wong WM; Mak LF; Wang X; Chu H; Cai JP; Jin DY; To KK; Chan JF; Yuen KY; Kok KH Emerg Microbes Infect; 2020 Dec; 9(1):1418-1428. PubMed ID: 32529952 [TBL] [Abstract][Full Text] [Related]
22. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Shannon A; Le NT; Selisko B; Eydoux C; Alvarez K; Guillemot JC; Decroly E; Peersen O; Ferron F; Canard B Antiviral Res; 2020 Jun; 178():104793. PubMed ID: 32283108 [TBL] [Abstract][Full Text] [Related]
23. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy. Goyal B; Goyal D ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186 [TBL] [Abstract][Full Text] [Related]
25. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19. Vardhan S; Sahoo SK Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628 [TBL] [Abstract][Full Text] [Related]
26. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Hall DC; Ji HF Travel Med Infect Dis; 2020; 35():101646. PubMed ID: 32294562 [TBL] [Abstract][Full Text] [Related]
27. Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy? Habtemariam S; Nabavi SF; Banach M; Berindan-Neagoe I; Sarkar K; Sil PC; Nabavi SM Arch Med Res; 2020 Oct; 51(7):733-735. PubMed ID: 32536457 [TBL] [Abstract][Full Text] [Related]
28. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms. Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875 [TBL] [Abstract][Full Text] [Related]
29. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study. Hosseini FS; Amanlou M Life Sci; 2020 Oct; 258():118205. PubMed ID: 32777300 [TBL] [Abstract][Full Text] [Related]
30. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA. Bello M; Martínez-Muñoz A; Balbuena-Rebolledo I J Mol Model; 2020 Nov; 26(12):340. PubMed ID: 33184722 [TBL] [Abstract][Full Text] [Related]
32. Architecture of a SARS-CoV-2 mini replication and transcription complex. Yan L; Zhang Y; Ge J; Zheng L; Gao Y; Wang T; Jia Z; Wang H; Huang Y; Li M; Wang Q; Rao Z; Lou Z Nat Commun; 2020 Nov; 11(1):5874. PubMed ID: 33208736 [TBL] [Abstract][Full Text] [Related]
33. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking. Silva Arouche TD; Reis AF; Martins AY; S Costa JF; Carvalho Junior RN; J C Neto AM J Nanosci Nanotechnol; 2020 Dec; 20(12):7311-7323. PubMed ID: 32711596 [TBL] [Abstract][Full Text] [Related]
34. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Elfiky AA Life Sci; 2020 May; 248():117477. PubMed ID: 32119961 [TBL] [Abstract][Full Text] [Related]